BELITE BIO, INC
H.C. Wainwright raised its price target on Belite Bio, Inc. ADR (NASDAQ:BLTE) to $214 from $200 and kept a Buy rating after the FDA accepted Belite Bio’s NDA for tinlarebant and granted Priority Review. The firm cited Phase 3 DRAGON results showing a 35.7% reduction in retinal lesion growth vs placebo. FDA PDUFA date is Feb. 12, 2027.
Belite Bio (BLTE) said the FDA accepted its tinlarebant NDA for Stargardt disease type I and granted priority review. A decision is expected Feb. 12, 2027. Priority review targets action in six months. The filing is based on Phase III DRAGON results showing a 35.7% reduction in atrophic lesion growth rate vs placebo. BLTE shares rose about 6.2% on Tuesday.
The FDA accepted and granted priority review to Belite Bio’s (Nasdaq: BLTE) New Drug Application for tinlarebant to treat Stargardt disease type 1. The Prescription Drug User Fee Act target action date is Feb. 12, 2027. The program previously received breakthrough therapy, fast track, and rare pediatric designations, and has orphan drug status in multiple regions.
Over the past 7 days, alphai's AI scored 3 news stories mentioning BLTE (BELITE BIO, INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent BLTE coverage spans regulation, insider activity and earnings.
In the last 30 days, BLTE insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($132K). The most active reporter was Lin Yu-Hsin, Chief Executive Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst PT hike is tied to a concrete FDA milestone (Priority Review), supporting a near-term positive risk skew into the Feb 12, 2027 PDUFA date.
Priority review acceptance increases the probability of a near-term regulatory catalyst and supports a positive risk-reward into the PDUFA-style decision window.
Priority review increases near-term regulatory momentum and can re-rate probability of approval for tinlarebant, supporting risk-on positioning into the decision window.
Fresh Phase 3 secondary endpoint data (qAF) plus reiterated primary endpoint success is a near-term positive catalyst for BLTE.
Insider open-market selling by a top medical officer is a modest, near-term sentiment datapoint but not a fundamental catalyst by itself.
alphai scores every news story that mentions BLTE with an AI model for sentiment and relevance, and aggregates insider trades from BELITE BIO, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright raised its price target on Belite Bio, Inc. ADR (NASDAQ:BLTE) to $214 from $200 and kept a Buy rating after the FDA accepted Belite Bio’s NDA for tinlarebant and granted Priority Review. The firm cited Phase 3 DRAGON results showing a 35.7% reduction in retinal lesion growth vs placebo. FDA PDUFA date is Feb. 12, 2027.
4 min readBelite Bio (BLTE) said the FDA accepted its tinlarebant NDA for Stargardt disease type I and granted priority review. A decision is expected Feb. 12, 2027. Priority review targets action in six months. The filing is based on Phase III DRAGON results showing a 35.7% reduction in atrophic lesion growth rate vs placebo. BLTE shares rose about 6.2% on Tuesday.
4 min readThe FDA accepted and granted priority review to Belite Bio’s (Nasdaq: BLTE) New Drug Application for tinlarebant to treat Stargardt disease type 1. The Prescription Drug User Fee Act target action date is Feb. 12, 2027. The program previously received breakthrough therapy, fast track, and rare pediatric designations, and has orphan drug status in multiple regions.
4 min readBelite Bio (NASDAQ:BLTE) reported additional secondary endpoint statistics from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1. The company said qAF stayed stable or fell about 2% at 25 months with tinlarebant versus about a 20% increase with placebo, and the trial previously met its primary endpoint, reducing retinal lesion growth by 35.7% versus placebo. BLTE shares rose about 3.11% to $154.74.
4 min readScholl Hendrik Peter (Chief Medical Officer) sold 10,000 indirectly-held shares of BELITE BIO, INC (BLTE) at an average of $145.24 ($143.90–$147.11, $1.45M total) across 5 trades on 2026-06-18.
2 min readScholl Hendrik Peter (Chief Medical Officer) sold 10,000 indirectly-held shares of BELITE BIO, INC (BLTE) at an average of $140.57 ($137.61–$145.02, $1.41M total) across 8 trades on 2026-06-16.
2 min readBelite Bio (NASDAQ: BLTE) said it has completed the rolling submission of its New Drug Application to the FDA for tinlarebant, an investigational once-daily oral therapy for Stargardt disease type 1 (STGD1). The NDA began in April 2026 under Breakthrough Therapy Designation. After the 60-day FDA review, a PDUFA target action date would be set, according to the company.
4 min readBelite Bio (NASDAQ: BLTE) said it completed a rolling NDA submission to the U.S. FDA for tinlarebant, an investigational once-daily oral therapy for Stargardt disease type 1 (STGD1). The filing began in April 2026 under Breakthrough Therapy Designation. After a 60-day FDA review, a PDUFA target action date will be set.
3 min readBelite Bio (NASDAQ: BLTE) said it completed the rolling submission of an NDA to the U.S. FDA for tinlarebant, an investigational once-daily oral therapy for Stargardt disease type 1 (STGD1). The NDA started in April 2026 under Breakthrough Therapy Designation. Belite said FDA review will take 60 days, after which a PDUFA target date may be set.
4 min readBelite Bio (NASDAQ: BLTE) said it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 4:00 pm ET. The company noted the webcast will be available on its investor relations site with 90-day replay access. Belite Bio’s lead candidate is tinlarebant.
1 min read
